The multivariate analysis in the PANTS (Personalising Anti-TNF Therapy in Crohn’s Disease) study demonstrated that low drug concentration at Week 14, for both IFX and ADA, predicted immunogenicity [27]. The gene discussed is TNF; the disease is Crohn disease.